Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Revisions for generic drug labeling

This article was originally published in The Tan Sheet

Executive Summary

Generic drug manufacturers will be responsible for monitoring any labeling changes for the reference listed drug for application to their own products, FDA says in a guidance on "Revising ANDA Labeling Following Revision of the RLD Label." The guidance asks ANDA sponsors to routinely monitor the Office of Generic Drugs' Labeling Review Branch Internet homepage, which will provide monthly updates of approved labeling changes for reference listed drugs with approved ANDAs. Previously, OGD notified ANDA sponsors when the approved labeling for an RLD had changed. The office will continue to notify generic firms in the case of labeling revisions connected with a "Dear Doctor" letter or other situations requiring immediate widespread professional notification

Topics

UsernamePublicRestriction

Register

PS091163

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel